SCHEMBL7934089

SCHEMBL7934089

Nc1ncccc1NCc1cc(NC(=O)c2cc3cc(Cl)cn3cn2)ccc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 7/20 0.44
GRM4 Q14833 6/20 0.36
BACE2 Q9Y5Z0 1/20 0.35
AURKA O14965 1/20 0.35
AURKB Q96GD4 1/20 0.35
HDAC4 P56524 2/20 0.35
MEF2D Q14814 1/20 0.35
MALT1 Q9UDY8 1/20 0.35
FADS1 O60427 1/20 0.35
ANO1 Q5XXA6 1/20 0.35
PDPK1 O15530 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC10 Q969S8 1/20 0.34
HDAC11 Q96DB2 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
HDAC9 Q9UKV0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7934113 0.89 BACE1 (0.51) BACE1GRM4BACE2AURKAAURKB
SCHEMBL7935588 0.87 BACE1 (0.59) BACE1GRM4AURKAAURKBHDAC6
SCHEMBL7940557 0.86 BACE1 (0.45) BACE1GRM4ANO1HDAC6
SCHEMBL7943303 0.82 BACE1 (0.52) BACE1BACE2
SCHEMBL7943486 0.81 NPC1 (0.48) BACE1AURKAAURKBHDAC1
SCHEMBL7944835 0.80 BACE1 (0.54) BACE1GRM4BACE2HDAC3HDAC1
SCHEMBL7942441 0.80 BACE1 (0.46) BACE1GRM4BACE2AURKAAURKB
SCHEMBL7939883 0.80 TP53 (0.55) BACE1
SCHEMBL7945292 0.80 BACE1 (0.52) BACE1BACE2
SCHEMBL7940554 0.80 BACE1 (0.47) BACE1GRM4BACE2AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885GRM4 2438/4885BACE2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.